Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback